Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 108Radiotherapy 45Docetaxel 44Radiotherapy, Intensity-Modulated 36Gemcitabine 31Fluorouracil 30camrelizumab 24toripalimab 21Drug Therapy 21Cetuximab 20apatinib 19Paclitaxel 16Carboplatin 16pembrolizumab 14Chemoradiotherapy 14Capecitabine 13Blood Specimen Collection 13sintilimab 12nimotuzumab 12Surveys and Questionnaires 10Surgical Procedures, Operative 10Endostatins 10Cyclophosphamide 9nedaplatin 8endostar protein 8durvalumab 8Nivolumab 8Neoadjuvant Therapy 8Induction Chemotherapy 8fludarabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Canagliflozin × Head & Neck × Clear all
NCT04073680 2020-05-21

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Petra Pharma

Phase 1/2 Unknown
60 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡